Patients who developed recurrent thrombosis underwent fewer aPL measurements per year than those without recurrence (median 1.0 vs 1.5 tests/year, P = 0.003), despite similar total number of aPL determinations performed (Supplementary Table S3). The gene discussed is FASLG; the disease is deep vein thrombosis.